@article{a95d76d68ee14731a0e953cefa6b42d7,
title = "Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts",
abstract = "Introduction: Hidradenitis suppurativa (HS) patients may be at increased risk of COVID-19 infection and complications from their medications and comorbidities. There is a lack of expert consensus on recommendations for the COVID-19 vaccine for HS patients. Herein, we aim to provide expert-driven consensus recommendations regarding COVID-19 vaccinations in HS patients. Methods: A modified Delphi consensus survey developed by a core committee of 7 dermatologist HS experts consisting of 4 demographic questions and 12 practice statements was distributed to the US HS Foundation-sponsored provider listserv. Participants were attending physician HS experts. Survey results were to be reviewed by the core group and revised and resubmitted until consensus (≥70% agreement) was achieved. Results: Among the 33 survey participants, there were 30 (87%) dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist. Consensus for all 12 statements on vaccine counseling and HS treatment counseling was achieved after the first round. Discussion/Conclusion: For now, this consensus can serve as a resource for clinicians discussing COVID-19 vaccination with their HS patients. These recommendations will need to be updated as new evidence on COVID-19 emerges.",
author = "Rick, {Jonathan W.} and De, {Devea R.} and Terri Shih and Afsaneh Alavi and Kirby, {Joslyn S.} and Naik, {Haley B.} and Frew, {John W.} and Sayed, {Christopher J.} and Hsiao, {Jennifer L.} and Shi, {Vivian Y.}",
note = "Funding Information: J.L.H. is on the board of directors for the HS Foundation (HSF) and is a consultant for Novartis and speaker for AbbVie. A.A. is consultant for Abbvie, BI, InflaRX, Janssen, Novartis, and UCB and investigator for BI and Processa. C.J.S. is on the board of directors of the HSF, has received research funding from Abbvie, Novartis, Incyte, InflaRx, Chemocentryx, and UCB, and has received honoraria for consulting and/or speaking from Abbvie, UCB, Novartis, and InflaRx. H.B.N. has received grant support from AbbVie, consulting fees from 23andme, Abbvie, and DAVA Oncology, advisory board fees from Boehringer Ingelheim, and is an investigator for Pfizer. She is also an Associate Editor for JAMA Dermatology and an unpaid board member of the US HSF. J.W.F. has conducted advisory work for Janssen, Boehringer Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie, and UCB, participated in trials for Pfizer, UCB, Boehringer Ingelheim, Eli Lilly, CSL, Janssen, and received research support from Ortho Dermatologics and Sun Pharma. J.S.K. is consultant for Abbvie, Bayer, Incyte, InflaRX, Janssen, Novartis, and UCB; on the speaker bureau for AbbVie; and received research funding from Incyte. V.Y.S. is on the board of directors for the HSF, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Menlo Therapeutics, Dermira, Burt{\textquoteright}s Bees, Galderma, Kiniksa, UCB, TARGET-DERM, Altus Lab, MYOR, Polyfin, GpSkin, and Skin Actives Scientific. Publisher Copyright: {\textcopyright} 2022 The Author(s).",
year = "2022",
month = jul,
day = "1",
doi = "10.1159/000521268",
language = "English (US)",
volume = "8",
pages = "287--290",
journal = "Skin Appendage Disorders",
issn = "2296-9195",
publisher = "S. Karger AG",
number = "4",
}